1 Introduction {#S1}
==============

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disease with strong genetic etiology. The rapid growth of genome sequencing capabilities has enabled the collection of large datasets and genome-wide association studies in the quest for causative mutations ([@R6], [@R14], [@R15], [@R16], [@R18], [@R25], [@R26], [@R29], [@R19]). Sequencing and data collection efforts such as those undertaken by the Simons Foundation Autism Research Initiative have thus far identified over 100 high confidence genes correlated to ASD and intellectual disability ([@R26], [@R1]). Expression studies have identified an additional 66 genes with a highly correlated regulatory pattern in both blood and brain samples of individuals with ASD ([@R8]).

Models explaining the genetic architecture of ASD include inherited and de novo alterations and have evolved to include polygenic, additive alterations ([@R27]). Despite an estimated 90% heritability of the disorder, only a small fraction of cases can be explained by known molecular causes ([@R2]), and typical approaches to detect pertinent genes often do not account for intergenic associations. Epistatic interactions have been proposed to explain a portion of the remaining unknown genetic etiology ([@R24], [@R7]). Due to the rarity of many alterations involved in the polygenic models, studies have largely been unable to achieve the statistical power necessary for pinpointing new genetic causes ([@R13], [@R10]).

Coalitional game theory (CGT) has been suggested as an enhanced signal detection method that takes into account the combinatorial role of groups of genes in a given condition. This tactic assumes synergy within coalitions to explain a given phenotype, where individual players are represented by genes. Genes that have the greatest average marginal contribution across all coalitions--the genes that play the most in coalitions associated with the disease phenotype--are selected as significant. Previous work has applied CGT approaches for differential gene expression analysis and has successfully identified groups of genes as contributing to Alzheimer's ([@R28]) and ASD ([@R11], [@R20]).

We propose that CGT can be effectively applied to gene alteration data to highlight candidate ASD genes, supporting the polygenic model. We demonstrate an example on 1,965 genomes of individuals in multiplex ASD families (1616 cases and 349 controls). Identifying inherited alterations in genes not previously linked to ASD, such as those presented here, could lead to more accurate diagnoses of the disorder and targeted, proactive therapeutic development against the combinations of underlying molecular causes. This approach could be similarly applied to other complex diseases with combinatorial molecular underpinnings.

2 Methods {#S2}
=========

2.1 Data source and preprocessing {#S3}
---------------------------------

We analyzed 30x-coverage whole genome sequencing data from the Hartwell Foundation's Autism Research and Technology Initiative (iHART), which has amassed one of the largest human disease genome sequencing efforts to-date. Specifically, we assessed the genomes and phenotypic measurements from 756 multiplex families containing at least two children affected by ASD, unaffected parents, and zero or more unaffected siblings.

Families grouped by the phenotypes of their children are as follows (number of children with ASD, number of neurotypical children): 380 (2, 0), 243 (2, 1), 62 (3, 0), 29 (3, 1), 23 (2, 2), 5 (3, 2), 4 (4, 0), 2 (3, 3), 2 (3, 4), 2 (4, 1), 2 (5, 0), 1 (4, 4), and 1 (5, 2) families. Quality control of the sequenced data included removal of non-mendelian variants, which removed sequencing error as well as de novo mutations. Removal of all parents led to an imbalance in the number of cases and controls included in the analysis.

To test the hypothesis of the impact of inherited mutations on the ASD phenotype, we restricted our attention to inherited mutations with highest predicted impact (termed likely gene disrupting, or LGD). We filtered the alteration space to include only loss-of-function variants that had high haplotype-aware consequences (CSQ impact = high) from the variant call format files (<http://samtools.github.io/bcftools>). For each variant, we predicted the inheritance pattern based on the mother's genotype, father's genotype, and the child's genotype. This included autosomal, pseudoautosomal, and sex-linked genes.

We grouped the alterations across all alleles in each gene for each sample, combining homozygous alternate variants and compound heterozygous variants for a given gene. We also included an allele frequency cutoff (keeping only those with a frequency ≤0.5) in order to prevent variants with high allele frequency from masking signal. Collapsing the data from allele to gene level, we encoded these alterations into a binary matrix, with 1 indicating the presence of at least one high impact alteration in a given gene for a given sample (homozygous alternate, compound heterozygous, or both), and 0 indicating that no such alteration existed in that gene/sample combination. Only genes with a high impact alteration in at least one sample were kept in the subsequent analyses.

2.2 Coalitional game theory method {#S4}
----------------------------------

We applied the coalitional game theory method as described by [@R20] to the iHART alteration data. Coalitional game theory studies the synergy among groups of players. Let *N* be a finite set of players (in our case, genes). We define a coalition *T* to be a subset of players (*T* ⊆ *N*), and we select a score function *v*: 2*^N^* → **R** which assigns a score to every possible coalition. We assume *v*(Ø) = 0. The fundamental concept of coalitional game theory is that players working together in a coalition may produce higher or lower scores than the sum of each of those players working individually. This means we assume there are cases such that
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Our goal was to identify players who tend to increase the score of any coalition they join. To do this, we calculated the Shapley value for each player. The Shapley value *ϕ~i~* is the marginal contribution of player *i* over all possible coalitions.
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For our analysis, we used the unanimity score given by [@R21]. Let *m* be the number of individuals in our dataset. Each individual *j* has a high impact alteration in a subset *M~j~* of genes. The unanimity score *u*(*T*, *j*) for coalition *T* and individual *j* is 1 if all *M~j~* altered genes are contained in the coalition (*M~j~* ⊆ *T*) and 0 otherwise. We then define our characteristic function *v* to be
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[@R21] show that this choice of *v* makes computing the Shapley values *ϕ~i~* tractable for large datasets. The algorithm took 16.793 minutes to run for 965 genes and 1,965 samples on 1 node of a computer cluster, with 4 cores and 32GB of memory. A detailed example of Shapley value calculation can be found in the electronic supplementary material provided by [@R20].

2.3 Game theory analysis {#S5}
------------------------

All statistical analyses and applications of coalitional game theory were performed using Bioconductor version 3.5 (<http://www.bioconductor.org/>) and R version 3.4.0 (<http://www.r-project.org/>). We removed all genes without any alterations across samples, as the corresponding Shapley values would be 0. This reduced the feature space of genes from 13,853 to 965 genes, resulting in a final boolean matrix of 965 genes and 1,965 samples (1,616 cases and 349 controls). In order to compute the Shapley values, the boolean matrix was split into two matrices corresponding to case and control: *B^case^* and *B^control^*. We adapted the script from [@R20] to compute the Shapley values using the boolean matrices.

We performed Comparative Analysis of Shapley value (CASh), a resampling-based multiple hypothesis testing procedure introduced in [@R20] to filter out genes with Shapley values that could be high due to chance. We used the function MTP from Bioconductor package "multtest" to compute a CASh p-value for each gene. We ran 1,000 nonparametric bootstrap re-samples with replacement on the matrices. The MTP produces unadjusted p-values for each gene, along with a bootstrap p-value, calculated via simulations. We filtered for only those genes that were significant at the 0.05 and 0.01 significance levels.

Given that our cases and controls could be related siblings and share inherited mutations, we reran coalitional game theory on randomly sampled cases and controls from each family (1 of each per eligible family). As the algorithm is run separately on the case and control binary matrices, none of the samples share familial connection when the Shapley values are computed. The gene identification process via CGT is presented in [Figure 1](#F1){ref-type="fig"}.

2.4 Functional analyses {#S6}
-----------------------

To elucidate potential associations with previously-correlated ASD gene candidates, we cross-referenced the CGT gene lists with both the high confidence SFARI genes list ([@R1]) and a set of genes found to be significantly dysregulated in both the blood and brain of individuals with autism, the Root 66 gene list ([@R8]), using the functional protein network analysis tool STRING (string-db.org). We also checked for network representation of the CGT genes using the Reactome Pathway Browser (reactome.org), a free, open-source, curated and peer-reviewed pathway database. We reported pathways enriched for CGT genes with FDR\<0.1.

3 Results {#S7}
=========

The filtration and binary conversion pre-processing steps yielded 1,616 cases and 349 controls with alteration information for 965 genes. We identified genes (CGT genes) as key contributors in the genetic coordination of ASD using coalitional game theory, as determined by the difference in Shapley value between cases and controls ([Figure 1](#F1){ref-type="fig"}). Sixty-seven genes showed statistical significance at the 0.05 significance level (p \< 0.05), with 23 of those genes significant at the 0.01 level (p \< 0.01) ([Table 1](#T1){ref-type="table"}). Rerunning coalitional game theory on randomly sampled cases and controls from each of the eligible families returned the same genes and confirmed that the family structure of the dataset did not confound the results.

Cross referencing CGT genes with high confidence ASD genes extracted the known biological functions represented by these candidate ASD genes. Nine of the CGT genes have protein products that directly interact with protein products of genes in the SFARI and Root 66 gene lists, as determined by the functional protein association networks tool STRING ([Figure 2](#F2){ref-type="fig"}).

Reactome pathway analysis detected 20 significant, non-overlapping functional categories (FDR \< 0.1). Of note, pathways representing axon guidance in developmental biology and related neurologic disorders (FDR=0.03 and FDR=0.0047), FGFR1- and insulin receptor-mediated signaling (FDR=0.0042 and FDR=0.034), the innate immune system (FDR=0.09), and olfactory signaling (FDR=0.0252) were enriched for CGT genes. Each of these biological functions has been previously associated with ASD ([@R3], [@R22], [@R17], [@R23], and [@R12]).

4 Discussion {#S8}
============

Whereas classical genome-wide association studies to pinpoint genes relevant to a biological condition focus on individual genes, coalitional game theory takes into account broader interactions between groups of genes leading to a phenotype. Calculating the Shapley value and filtering for the genes with the highest average marginal contribution over all possible alteration combinations can enable detection of significant gene coaltions and thus boost biologically informative signal. This cooperative view of the alteration landscape more comprehensively accounts for polygenic complexity and may be essential for understanding ASD's genetic architecture.

In this study, we applied cooperative game theory to a large collection of whole genomes from multiplex autism families in an effort to find cooperative signal among coalitions that relate specifically to the autism phenotype. We focused our analysis on inherited gene disrupting mutations to pursue the hypothesis of ASD being a largely inherited, polygenic disorder. Our sample set consisted of 1,616 cases and 349 family-based controls (due to the exclusion of parents), where a gene was assigned a 1 if it contained at least 1 or more such mutations. By analyzing the cooperative contribution of each gene to the phenotype, we found 67 genes that significantly increased the likelihood of a coalition "winning the game" whenever they joined the coalition, where winning refers to the strength of the association to the autism phenotype. Through random sampling, we found that these genes did not appear to be an artifact of the family structure of our data.

Compellingly, 9 of these genes have published links to autism through either DNA or RNA-based analysis ([@R5]). Further supporting the role of these genes in autism, we found their protein products to be enriched for interaction with the protein products of known autism candidate genes, often interacting just one node away from hubs of connected ASD gene products. Pathway enrichment analyses revealed that signaling pathways in ASD-associated biological functions such as axon development and innate immunity are enriched for CGT genes.

Potential limitations of this work entail the exclusion of alterations in the non-coding regions, as well as the exclusion of low CSQ impact variants within genes. This limits our ability to find links between the disease phenotype and more subtle genomic and non-coding variation. Exploring such nuanced alterations could shed light on additional high impact, potentially causative molecular states for a disease under consideration. Replication of our analyses and functional characterization will be necessary for comprehensively evaluating the biological implications of our findings. Additionally, many of the genes that were identified via CGT are pseudogenes and have not yet been well studied, making the analysis of such regions even more pressing.

Probing into the specifics of the protein-protein interactions between CGT genes and known ASD candidates, as well as into the groups of co-altered gene coalitions in case subgroups, may provide further mechanistic insights into the underlying molecular causes of ASD. Identifying similarly statistically correlated genes through additional genome-wide ASD gene alteration datasets may elucidate higher degree epistatic connections that can be targeted in both diagnosis and treatment of ASD. Stratifying patients through PCA according to their landscape of co-alterations could improve the precision of diagnosis, and knocking out groups of genes identified in functional assays could reveal potent combinations in therapeutically targeting the molecular underpinnings of ASD.

Coalitional game theory thus serves as a powerful approach to characterize epistatic interactions that may only emerge in a multi-gene model. Capitalizing on the unparalleled rate of genomes being sequenced in increasingly diverse demographic and disease populations, unconventional yet statistically sound tools such as CGT may accelerate the search for biomarkers, particularly in polygenic conditions of mental health.

This work was supported in part by the Hartwell Foundation award to D.P. Wall and the Hartwell Autism Research and Technology Initiative (iHART).

![Data analysis flow diagram, starting from the sequenced genomes to identification of significant genes through coalitional game theory.](nihms976754f1){#F1}

![Functional protein interactions between coalitional game theory genes, SFARI genes, and Root 66 genes. SFARI genes are in black, Root 66 genes are in gray, and CGT genes (p \< 0.05) are in white. Nine CGT genes have direct links to known candidate ASD genes.](nihms976754f2){#F2}

###### 

Genes selected through coalitional game theory at two levels of significance. The 44 genes listed in p\<0.05 are the subset of the 67 genes not in p\<0.01.

  Significance          Gene symbol
  --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  p**-**value \< 0.05   A2ML1, AC008703.1, AC093911.1, ALOX15P2, ATP13A5, BORA, BPIFB5P, C12orf60, C3orf35, CARD8, CCDC26, CCDC7, CDH15, COQ10A, CTC-525D6.1, DUSP16, ERCC6L2, FAM151A, FAM81B, FLG, GBGT1, HLA-K, LGALS8, MAGEC3, MYCT1, OR2T4, OR4Q2, OR6C1, OR8B3, RBAK-RBAKDN, RP11-104E19.1, RP11-160N1.10, RP11-404K5.2, RP11-56H2.2, RP11-618I10.2, RP11-738O11.13, SLC3A1, SSPO, TCP11, TRBV6-7, TRIM48, UBXN11, YME1L1, ZNF99
  p-value \< 0.01       AF196972.4, AP002856.6, ATP6V1B1, C10ORF68, CDRT15P1, CTB-23I7.1, CTD-2130O13.1, CTD-2509G16.2, GEN1, KRT43P, MDP1, MPRIP, NT5C1B, OR4P4, OR5M10, OR5M11, OR8I2, PRIM2, RP11-15E18.4, RP11-283G6.4, RP11-705C15.2, SSXP3, VWA7
